Position of the Transparency Council – Kisqali (ribociclib)
At its meeting on 19 May 2025, the Transparency Council adopted position No. 62/2025 on the appraisal of the drug Kisqali (ribociclib) under the B.9.FM drug program. “Treatment of patients with breast cancer (ICD-10: C50)”